Almost 15 years after the approval of the first GLP-1 agonist, the US...
From injections to pills: FDA approves first oral GLP-1 for type 2 diabetes
Almost 15 years after the approval of the first GLP-1 agonist, the US FDA has approved the first oral version of this treatment approach for type 2 diabetes. What are the benefits of a pill-based, rather than injectable version, of GLP-1 analogues for this patient population?
Shionogi and Hsiri to develop mycobacterial disease therapies
Japanese pharmaceutical firm Shionogi has signed a licence agreement with Hsiri Therapeutics for the discovery and development of therapies for non-tuberculous mycobacterial (NTM) diseases, as well as tuberculosis (TB).
Alexion and Stealth to develop elamipretide for mitochondrial diseases
Biopharmaceutical company Alexion Pharmaceuticals has entered a deal with biotechnology firm Stealth BioTherapeutics to develop and commercialise elamipretide to treat mitochondrial diseases.
Sanofi Active Ingredient Solutions to Appear at CPhI Worldwide, 5-7 November
Sanofi Active Ingredient Solutions are pleased to announce we will be appearing at CPhI Worldwide on 5-7 November at Messe Frankfurt in Frankfurt, Germany.
Novo Nordisk and bluebird bio to develop genetic disease therapies
Danish healthcare company Novo Nordisk has allied with US-based gene therapies firm bluebird bio to develop in vivo genome editing products for the treatment of genetic diseases.
Elemental Impurity Analysis in Pharmaceuticals and Implementation of ICH Q3D
Elemental impurities have been a hot topic since 2009 when the International Conference of Harmonisation (ICH) commenced work on a new standard to provide a global policy to limit these impurities in drug products and ingredients.
Improvements to joints and skin see Taltz outscore Humira
Taltz met superiority criteria for the study’s primary endpoint, improvements to joints and skin symptoms in a head-to-head psoriatic arthritis trial.
GSK and Lyell partner to develop cell therapies for cancer
GlaxoSmithKline (GSK) has partnered with US-based biotechnology firm Lyell Immunopharma to develop technologies to boost cancer cell therapies.
The drugs fighting memory loss
Researchers in Toronto have developed an experimental drug that appears to renew the underlying brain impairments causing memory loss, fuelling hopes that a treatment for cognitive decline linked to depression and aging may be on the horizon. Abi Millar takes a look.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.